Similar conditions were also found in SLC45A2-AMACR and Pten-NOLC1 fusion: 80% (20/25) SLC45A2-AMACR and 76% (19/25) Pten-NOLC1 were detected in the prostate cancer samples, while the detection rate dropped to 48% (12/25) in the matched blood samples for SLC45A2-AMACR and 40% (10/25) for Pten-NOLC1. Here, SLC45A2 is linked to prostate carcinoma.